Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Part of paid clinical trials in Duarte, California.
- Sponsor
- University of Southern California
- Study ID
- NCT03858205
- Status
- Recruiting
Conditions
- Bone Pain
- Metastatic Malignant Neoplasm in the Bone
- Plasma Cell Myeloma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Quality-of-Life Assessment — OTHERAncillary studies
- Questionnaire Administration — OTHERAncillary studies
- Radiation Therapy — RADIATIONReceive low-dose radiation therapy
Study Details
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.
Key Dates
- Start date
- Mar 11, 2019
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2026
- Completion
- Mar 11, 2027
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (low-dose radiation therapy)Patients receive low-dose radiation therapy at consecutive business days 1 and 2 in the absence of disease progression or unacceptable toxicity. Patients with no pain relief may receive additional radiotherapy at 4 weeks following initial radiotherapy.
Primary Outcome Measure
Pain response [ Time Frame: Up to 6 months after completion of radiation therapy ]
Central Contacts
- Christine Duran323-865-0371
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Savita V Dandapani, MD (PRINCIPAL_INVESTIGATOR) |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | Leslie Ballas, MD (PRINCIPAL_INVESTIGATOR) |
| Los Angeles General Medical Center | Los Angeles | California | 90033 | Adam Garsa, MD (PRINCIPAL_INVESTIGATOR) |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Adam Garsa, MD (PRINCIPAL_INVESTIGATOR) |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 | Mohammad K. Khan (PRINCIPAL_INVESTIGATOR) |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Andrea K. Ng (PRINCIPAL_INVESTIGATOR) |
| University of Minnesota - Masonic Cancer Center | Minneapolis | Minnesota | 55455 | Stephanie Terezakis, MD (PRINCIPAL_INVESTIGATOR) |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Richard L. Bakst (PRINCIPAL_INVESTIGATOR) |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | John Plastaras, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Duarte, CA
Related Studies
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Duarte, California
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPHASE3 · Recruiting · ECOG-ACRIN Cancer Research Group · Anchorage, Alaska
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaPHASE2 · Recruiting · Emory University · Atlanta, Georgia
- Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple MyelomaRecruiting · Roswell Park Cancer Institute · Buffalo, New York